A Perspective and Multicenter Phase II Trial of Tirelizumab Combined With R2-ICE Regimen (Rituximab, Lenalidomide, Ifosfamide, Carboplatin, Etoposide) in the Treatment of Refractory or Relapse DLBCL or HGBL

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05050630

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:29.934870+00:00

Published At

2021-09-20T00:00:00+00:00

Record Updated At

2021-09-20

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Age Range \u226516 Years, Gender Unlimited", "Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma", "Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed", "At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin\u0027s and Non-Hodgkin\u0027s Lymphoma", "ECOG Physical Status Score is 0-3", "The Researchers Judged That Life Expectancy Was at Least Three Months", "Understand and Voluntarily Sign Written Informed Consent"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2021-09-20"

protocolSection.identificationModule.nctId

"NCT05050630"

protocolSection.identificationModule.officialTitle

"A Perspective and Multicenter Phase II Trial of Tirelizumab Combined With R2-ICE Regimen (Rituximab, Lenalidomide, Ifosfamide, Carboplatin, Etoposide) in the Treatment of Refractory or Relapse DLBCL or HGBL"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Age Range ≥16 Years, Gender Unlimited (protocolSection.conditionsModule.conditions)
• Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed (protocolSection.conditionsModule.conditions)
• At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma (protocolSection.conditionsModule.conditions)
• ECOG Physical Status Score is 0-3 (protocolSection.conditionsModule.conditions)
• The Researchers Judged That Life Expectancy Was at Least Three Months (protocolSection.conditionsModule.conditions)
• Understand and Voluntarily Sign Written Informed Consent (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.